Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (Nasdaq: ALGS) announced that the USAN Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, an investigational therapy for chronic hepatitis B virus (HBV) infection. The name is intended to provide consistent identification and support international recognition and transparency.

The company said the name, shortened to “pevy,” is the first generic name assigned to a compound at Aligos and comes as the program advances through the ongoing Phase 2 B-Supreme study. The announcement highlights a regulatory-naming milestone rather than clinical readouts or approvals.

Aligos Therapeutics (Nasdaq: ALGS) will present at the H.C. Wainwright Liver Disease Conference on October 21–22, 2025. Members of management will deliver a company presentation covering recent clinical and corporate developments.

Investors can watch a live webcast via the Presentation & Events section on Aligos’ investor website at www.aligos.com. A replay will be available for at least 30 days after the presentation.

Aligos Therapeutics (Nasdaq: ALGS) announced eight abstracts accepted for The Liver Meeting® 2025 (Nov 7–11, 2025), including one oral presentation on 96-week and post-treatment follow-up data from the Phase 1 monotherapy study of ALG-000184, a capsid assembly modulator for chronic hepatitis B (HBV).

Highlights include an oral session on Nov 9, 2025 reporting that once-daily 300 mg ALG-000184 "demonstrates potent suppression of HBV DNA," a poster reporting sustained reduction of HBV antigen levels during an 8-week follow-up after 96 weeks of treatment, and multiple preclinical posters on CAM compounds and siRNA candidates for liver disease.

Aligos Therapeutics (Nasdaq: ALGS) announced six preclinical presentations at the 2025 International HBV Meeting in Berlin, including three oral presentations. The presentations showcase the company's research in liver and viral diseases, particularly focusing on ALG-000184 and a new antisense oligonucleotide (ASO) approach for hepatitis delta virus (HDV) treatment.

Key highlights include the first presentation of ALG-000184's direct effects in reducing HBV cccDNA in preclinical settings, supporting clinical observations of HBV antigen reductions in patients. Additionally, the company is expanding its pipeline with an ASO program for HDV treatment, targeting viral genome destruction as a potential cure strategy for HDV coinfection, which typically leads to more rapid disease progression.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025.

The company's management will deliver an on-demand presentation, which will be available through the Presentation & Events section on Aligos' investor relations website. The webcast recording will remain accessible for at least 30 days after the presentation.

Aligos Therapeutics (Nasdaq: ALGS) has appointed Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs. Dr. Polo brings significant experience in global regulatory affairs, particularly from his roles at Shionogi Inc. and Johnson & Johnson, where he was instrumental in the COVID-19 vaccine rollout.

Dr. Polo joins Aligos as the company advances its ALG-000184 through Phase 2 B-SUPREME study. His extensive background includes leading development teams, pharmacovigilance programs, and regulatory strategies for infectious diseases, vaccines, and global public health.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced inducement grants for newly hired employees. The Compensation Committee approved non-qualified stock options to purchase 42,300 shares on August 12, 2025.

The grants, issued under Aligos' 2024 Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. The exercise price equals the closing price of Aligos' common stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are exclusively for new hires.

Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing in its Phase 2 B-SUPREME study of ALG-000184 for chronic hepatitis B virus (HBV) infection treatment. The study will evaluate 200 untreated subjects over 48 weeks, comparing ALG-000184 monotherapy to tenofovir disoproxil fumarate.

The randomized, double-blind study will assess both HBeAg+ and HBeAg- adult subjects, with primary endpoints focusing on HBV DNA levels. The trial will also evaluate safety, pharmacokinetics, and various biomarkers. Interim data is expected in 2026, with topline results anticipated in 2027.

Aligos Therapeutics (Nasdaq: ALGS) reported Q2 2025 progress and financial results, highlighting significant advancements in their liver and viral disease pipeline. The company's lead candidate, ALG-000184, is initiating Phase 2 B-SUPREME study for chronic HBV infection across multiple countries, with dosing expected to commence shortly. The Phase 1 study showed promising 96-week data with 100% of subjects achieving HBV DNA suppression.

The company reported positive Phase 2a HERALD data for ALG-055009, their MASH treatment candidate, demonstrating significant liver fat reduction and improvements in atherogenic lipids. Financial position remains strong with $122.9 million in cash as of June 30, 2025, providing runway into second half of 2026. Q2 2025 resulted in a net loss of $15.9 million, with R&D expenses at $14.0 million and G&A expenses at $5.6 million.